Oncocyte appoints Andrea James as CFO, effective June 17, 2024

Insight Molecular Diagnostics Inc.

Andrea James appointed CFO; previously Chief Communications Officer at Axon Enterprise (AXON) and IR roles at Tesla.
Compensation: $325,000 base salary, 50% target bonus; option for 200,000 shares and 100,000 RSUs (subject to shareholder approval).
CEO Josh Riggs cites James' experience in capital raising and IR as company nears commercial launch.
James Liu remains Senior Director, Controller & Principal Accounting Officer.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Andrea James

Chief Financial Officer

IMDX · Insight Molecular Diagnostics Inc.

Effective: 2024-06-17
Filed: June 17, 2024, 7:59 PM ET

On June 17, 2024, the Board of Directors (the “Board”) of Oncocyte Corporation (the “Company”) appointed Andrea James to serve as the Company’s Chief Financial Officer, effective June 17, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Andrea James was appointed as Chief Financial Officer at Insight Molecular Diagnostics Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On June 17, 2024, the Board of Directors (the “Board”) of Oncocyte Corporation (the “Company”) appointed Andrea James to serve as the Company’s Chief Financial Officer, effective June 17, 2024.

View on SEC.gov

Insight Molecular Diagnostics Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-024108

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.